ICARuS II (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Multicenter, Randomized Phase II Trial of Normothermic Intraperitoneal Chemotherapy and Intravenous Chemotherapy After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma

Inclusion Criteria: * Patient age 18 years or older, both sexes. * Clinical diagnosis of MPM at enrolling institution. * Prior to randomization, intraoperative pathologic confirmation of epithelioid MPM at enrolling institution. * Complete or near-complete CRS achieved. * Patient must be planning to undergo complete cytoreduction of all peritoneal disease. * ECOG performance status ≤ 1. * Hematology: ANC ≥ 1,500/µl. * Platelets \> 75,000/µl. * Adequate renal function: creatinine \< 1.5× the upper limit of normal (ULN) or calculated creatinine clearance of ≥50 ml/min. * Adequate hepatic functi…